霍奇金病中MVPP疗法的药物剂量强度测量
Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.
作者信息
Green J A, Dawson A A, Fell L F, Murray S
出版信息
Br J Clin Pharmacol. 1980 May;9(5):511-4. doi: 10.1111/j.1365-2125.1980.tb05847.x.
Abstract
The dose of combination chemotherapy in Hodgkin's disease is commonly calculated from a formula based on the body surface area. A method is described for measuring the intensity of combination chemotherapy actually received compared to the calculated planned dose. The technique is applied to 56 patients receiving mustine, vinblastine, procarbazine and prednisolone, but would also be suitable for other cytotoxic regimens. The planned dosage intensity had to be significantly reduced in over half of the patients because of marrow toxicity. Splenectomized patients received a higher dose intensity than those in whom the procedure was not performed.
摘要
霍奇金病联合化疗的剂量通常根据基于体表面积的公式来计算。本文描述了一种方法，用于测量实际接受的联合化疗强度与计算出的计划剂量相比的情况。该技术应用于56例接受氮芥、长春花碱、丙卡巴肼和泼尼松龙治疗的患者，但也适用于其他细胞毒性治疗方案。由于骨髓毒性，超过半数的患者不得不显著降低计划的剂量强度。脾切除患者比未进行该手术的患者接受了更高的剂量强度。
相似文献
1
Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.
Br J Clin Pharmacol. 1980 May;9(5):511-4. doi: 10.1111/j.1365-2125.1980.tb05847.x.
2
Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease.
Eur J Cancer. 1991;27(8):1002-6. doi: 10.1016/0277-5379(91)90268-i.
3
The cure of Hodgkin's disease with drugs.
Adv Intern Med. 1983;28:277-302.
4
Combination chemotherapy in generalized Hodgkin's disease.
Br Med J. 1970 Jul 4;3(5713):7-10. doi: 10.1136/bmj.3.5713.7.
5
The treatment of stage IIIA Hodgkin's disease.
J Clin Oncol. 1983 Dec;1(12):745-9. doi: 10.1200/JCO.1983.1.12.745.
6
You're all right, Jack.
Nurs Times. 1988;84(29):28-31.
7
MVPP chemotherapy combined with radiotherapy in the treatment of Hodgkin's disease in children: long-term results.
Am J Pediatr Hematol Oncol. 1984 Winter;6(4):462-5. doi: 10.1097/00043426-198424000-00013.
8
Erythroleukaemia following treatment of Hodgkin's disease.
Clin Lab Haematol. 1982;4(4):417-9. doi: 10.1111/j.1365-2257.1982.tb00487.x.
9
[Effect of splenectomy on the leukocyte count during the treatment of children with Hodgkin's disease].
Wiad Lek. 1984 Sep 1;37(17):1320-5.
10
ChlVPP chemotherapy in advanced Hodgkin's disease.
Eur J Cancer Clin Oncol. 1989 Mar;25(3):557-61. doi: 10.1016/0277-5379(89)90270-8.
引用本文的文献
1
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs.
Eur J Hosp Pharm. 2023 Nov;30(6):328-332. doi: 10.1136/ejhpharm-2021-002998. Epub 2022 Jan 20.
2
Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting.
J Cancer Res Clin Oncol. 2017 Dec;143(12):2535-2543. doi: 10.1007/s00432-017-2509-0. Epub 2017 Aug 20.
3
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
PLoS One. 2015 Apr 24;10(4):e0123978. doi: 10.1371/journal.pone.0123978. eCollection 2015.
4
A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.
BMC Cancer. 2015 Apr 15;15:288. doi: 10.1186/s12885-015-1287-9.
5
Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging.
World J Surg. 1995 Nov-Dec;19(6):836-42. doi: 10.1007/BF00299780.
6
Dose intensity analysis in advanced ovarian cancer patients.
Br J Cancer. 1993 Jan;67(1):190-7. doi: 10.1038/bjc.1993.33.
7
Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.
Br J Cancer. 1989 Apr;59(4):645-9. doi: 10.1038/bjc.1989.131.
8
Evaluation of systemic chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin for advanced bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
Cancer Chemother Pharmacol. 1992;30 Suppl:S85-9. doi: 10.1007/BF00686950.
本文引用的文献
1
Tolerance to chemotherapy after prior irradiation for Hodgkin's disease.
Ann Intern Med. 1970 Apr;72(4):505-9. doi: 10.7326/0003-4819-72-4-505.
2
Combination chemotherapy in generalized Hodgkin's disease.
Br Med J. 1970 Jul 4;3(5713):7-10. doi: 10.1136/bmj.3.5713.7.
3
Report of the Committee on Hodgkin's Disease Staging Classification.
Cancer Res. 1971 Nov;31(11):1860-1.
4
Combination chemotherapy in advanced and recurrent Hodgkin's disease.
Natl Cancer Inst Monogr. 1973 May;36:395-402.
5
Splenectomy effects on chemotherapy in Hodgkin's disease.
Arch Intern Med. 1973 Mar;131(3):362-6.
6
Causes of death in patients with malignant lymphoma.
Am J Med Sci. 1974 Aug;268(2):97-106. doi: 10.1097/00000441-197408000-00003.
7
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Blood. 1976 Feb;47(2):211-22.
8
Infections in patients with malignant lymphoma treated with combination chemotherapy.
Cancer. 1977 Mar;39(3):1018-25. doi: 10.1002/1097-0142(197703)39:3<1018::aid-cncr2820390304>3.0.co;2-n.
Zotero 插件